Patents by Inventor Munehiro Noda
Munehiro Noda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220226944Abstract: A method for manufacturing a sintered gear comprising the steps of: preparing a cylindrical green compact; gear-cutting the green compact with a hob; and sintering the gear-hobbed green compact, wherein the hob is such that a ratio of a number of cutting edges thereof per round to a number of starts thereof exceeds 8.Type: ApplicationFiled: April 28, 2020Publication date: July 21, 2022Applicants: Sumitomo Electric Industries, Ltd., Sumitomo Electric Sintered Alloy, Ltd.Inventors: Kazunari SHIMAUCHI, Tomoyuki UENO, Tomoyuki ISHIMINE, Munehiro NODA
-
Publication number: 20220152701Abstract: A method of making a sintered body includes a step of preparing raw material powder containing powder of inorganic material, a step of producing a powder compact having a high-density portion with a relative density of 93% or more and a low-density portion with a relative density of less than 93% by compressing the raw material powder injected into a mold, a step of producing a machined compacted part by machining at least the high-density portion of the powder compact, and a step of sintering the machined compacted part to make a sintered body, wherein a perimeter shape of a cavity constituted by the mold in a cross-section perpendicular to an axial direction of the mold is such than a maximum stress applied to an inner perimeter surface of the mold during a compacting process using the mold is less than or equal to 2.Type: ApplicationFiled: April 13, 2020Publication date: May 19, 2022Applicants: SUMITOMO ELECTRIC INDUSTRIES, LTD., SUMITOMO ELECTRIC SINTERED ALLOY, LTD.Inventors: Tomoyuki ISHIMINE, Shigeki EGASHIRA, Munehiro NODA, Takayuki TASHIRO, Kazunari SHIMAUCHI
-
Publication number: 20210162499Abstract: A method for manufacturing a sintered member includes a step of preparing a raw material powder containing an iron-based powder; a step of forming a green compact having a relative density of 97% or more and having a solid cylindrical shape or hollow cylindrical shape by compacting the raw material powder; and a step of sintering the green compact. The raw material powder contains at least one of a mixed powder containing pure iron powder and Ni powder and an iron alloy powder containing Ni as an additive element. The total amount of the Ni powder and Ni serving as the additive element in the raw material powder is 1 mass % or more.Type: ApplicationFiled: May 8, 2018Publication date: June 3, 2021Inventors: Tomoyuki ISHIMINE, Shigeki EGASHIRA, Munehiro NODA
-
Publication number: 20200208244Abstract: A sintered material made of an iron-based alloy is provided, wherein a content of Ni is more than 0.2 mass % and 10 mass % or less in an entire iron-based alloy; a content of C is more than 0 mass % and 2.0 mass % or less in the entire iron-based alloy; at least one element selected from Mo, Mn, Cr B and Si is more than 0 mass % and 5.0 mass % or less in total in the entire iron-based alloy; and a rest of the iron-based alloy is Fe and incidental impurities. A content of Ni in a local region of the iron-based alloy is more than 0.2 mass % and less than 21 mass %. A relative density is 97% or more.Type: ApplicationFiled: July 19, 2018Publication date: July 2, 2020Inventors: Shigeki EGASHIRA, Tomoyuki ISHIMINE, Munehiro NODA, Takashi SEKIYA
-
Patent number: 8445649Abstract: An antibody provided by the present invention has a low reactivity with amyloid precursor proteins, and has a higher reactivity with amylospheroids than with amyloid ? fibrils or monomeric amyloid ?-proteins. According to the present invention, an antibody is provided that has a higher reactivity with amylospheroids than with amyloid precursor proteins, and has any one or more of the following properties: (i) a higher activity with amylospheroids than with amyloid ? fibrils; (ii) a higher reactivity with amylospheroids than with monomeric amyloid ?-proteins; and (iii) an activity of inhibiting neuronal cell death induced by amylospheroids.Type: GrantFiled: October 29, 2008Date of Patent: May 21, 2013Assignee: Tao Health Life Pharma Co., Ltd.Inventors: Minako Hoshi, Michio Sato, Shoji Ideno, Koji Naito, Satoshi Horie, Munehiro Noda, Hajime Horii
-
Publication number: 20100297662Abstract: An antibody provided by the present invention has a low reactivity with amyloid precursor proteins, and has a higher reactivity with amylospheroids than with amyloid ? fibrils or monomeric amyloid ?-proteins. According to the present invention, an antibody is provided that has a higher reactivity with amylospheroids than with amyloid precursor proteins, and has any one or more of the following properties: (i) a higher activity with amylospheroids than with amyloid ? fibrils; (ii) a higher reactivity with amylospheroids than with monomeric amyloid ?-proteins; and (iii) an activity of inhibiting neuronal cell death induced by amylospheroids.Type: ApplicationFiled: October 29, 2008Publication date: November 25, 2010Inventors: Minako Hoshi, Michio Sato, Shoji Ideno, Koji Naito, Satoshi Horie, Munehiro Noda, Hajime Horii
-
Patent number: 7084331Abstract: The present invention provides a rice plant that shows enhanced growth and increased seed production, which also enables reduction of the use of chemical fertilizers. In the present invention, a nitrogen-fixing endophytic bacterium is isolated from bacteria symbiotically inhabiting natural plants, the isolated endophytic bacterium is artificially proliferated and then artificially inoculated into rice plants, and thus, the nitrogen-fixing endophytic bacteria are allowed to infect to rice plants.Type: GrantFiled: May 2, 2002Date of Patent: August 1, 2006Assignees: Mayekawa Mfg. Co., Ltd.Inventors: Tsuyoshi Isawa, Naoya Hiruma, Takahiro Imada, Munehiro Noda, Yohsuke Kurihara, Madoka Kon
-
Patent number: 7037879Abstract: The objective of the present invention is to confer pest resistance to plants of Poaceae without using any chemically synthesized pesticides. The pest resistance can be conferred to plants of Poaceae by isolating from a natural plant an endophytic bacterium capable of expressing pest resistance, artificially culturing the endophytic bacterium, and introducing the bacteria to a Poaceae plant of interest.Type: GrantFiled: May 2, 2002Date of Patent: May 2, 2006Assignee: Society for Techno-Innovation of Agriculture Forestry Fisheria and Mayekawa Mfg. Co., Ltd.Inventors: Takahiro Imada, Naoya Hiruma, Tsuyoshi Isawa, Munehiro Noda, Yohsuke Kurihara, Madoka Kon
-
Publication number: 20030195117Abstract: The objective of the present invention is to confer pest resistance to plants of Poaceae without using any chemically synthesized pesticides.Type: ApplicationFiled: May 2, 2002Publication date: October 16, 2003Inventors: Takahiro Imada, Naoya Hiruma, Tsuyoshi Isawa, Munehiro Noda, Yohsuke Kurihara, Madoka Kon
-
Patent number: 6617133Abstract: The invention provides a process for purifying recombinant human serum albumin (rHSA) by heating a-culture medium containing rHSA and the rHSA-producing host cells, feeding said heated solution upwardly into a fluidized bed in which adsorbent particles are suspended to effect contacting with the adsorbent particles and then recovering the adsorbed fraction containing the rHSA, and a composition comprising rHSA which shows a A350/A280 ratio of below 0.015, when formulated into a 25% solution of said albumin.Type: GrantFiled: May 24, 1999Date of Patent: September 9, 2003Assignee: Mitsubishi Pharma CorporationInventors: Munehiro Noda, Akinori Sumi, Takao Ohmura, Kazumasa Yokoyama
-
Publication number: 20030135898Abstract: [Problems to be Solved]Type: ApplicationFiled: May 2, 2002Publication date: July 17, 2003Inventors: Tsuyoshi Isawa, Naoya Hiruma, Takahiro Imada, Munehiro Noda, Yohsuke Kurihara, Madoka Kon
-
Patent number: 5986062Abstract: Human serum albumin obtained by gene manipulation techniques can be purified by a combination of specified steps in which a culture supernatant obtained from a human serum albumin-producing host is subjected to ultrafiltration, heat treatment, acid treatment and another ultrafiltration, followed by subsequent treatments with a cation exchanger, a hydrophobic chromatography carrier and an anion exchanger, and by salting-out to thereby obtain a pure form of human serum albumin which contains substantially no proteinous and polysaccharide contaminants, which is formulated into a pharmaceutical preparation. The thus obtained human serum albumin can further be purified by treating recombinant human serum albumin with a hydrophobic chromatography carrier at pH of 2 to 5 and a salt concentration of 0.4 to 1 and exposing the carrier to a pH of 6 to 8 and a salt concentration of 0.01 to 0.Type: GrantFiled: October 3, 1995Date of Patent: November 16, 1999Assignee: The Green Cross CorporationInventors: Takao Ohmura, Akinori Sumi, Wataru Ohtani, Naoto Furuhata, Kazuya Takeshima, Kaeko Kamide, Munehiro Noda, Masahide Kondo, Syoichi Ishikawa, Kazuhiro Oohara, Kazumasa Yokoyama, Nagatoshi Fujiwara
-
Patent number: 5962649Abstract: The invention provides a process for purifying recombinant human serum albumin (rHSA) by heating a culture medium containing rHSA and the rHSA-producing host cello, feeding said heated solution upwardly into a fluidized bed in which adsorbent particles are suspended to effect contacting with the adsorbent particles and then recovering the adsorbed fraction containing the rHSA, and a composition comprising rHSA which shows a A35D/A280 ratio of below 0.015, when formulated into a 25% solution of said albumin.Type: GrantFiled: August 31, 1995Date of Patent: October 5, 1999Assignee: Yoshitomo Pharmaceutical Industries, Ltd.Inventors: Munehiro Noda, Akinori Sumi, Takao Ohmura, Kazumasa Yokoyama
-
Patent number: 5710253Abstract: A method for decoloring a recombinant human serum albumin by treating the albumin with a reducing agent is disclosed. Also, a method for decoloring a recombinant human serum albumin by treating the albumin with a method removing free polysaccharides with a cation exchanger followed by heat treatment is disclosed. The present invention provides a recombinant human serum albumin, coloring of which is fully suppressed by preventing binding of certain coloring components, which are contained in the raw materials or contaminants secreted by a microorganism, to human serum albumin so as not to cause coloring of the human serum albumin.Type: GrantFiled: December 19, 1994Date of Patent: January 20, 1998Assignee: The Green Cross CorporationInventors: Wataru Ohtani, Naoto Furuhata, Akinori Sumi, Munehiro Noda, Takao Ohmura
-
Patent number: 5521287Abstract: Human serum albumin obtained by gene manipulation techniques can be purified by a combination of specified steps in which a culture supernatant obtained from a human serum albumin-producing host is subjected to ultrafiltration, heat treatment, acid treatment and another ultrafiltration, followed by subsequent treatments with a cation exchanger, a hydrophobic chromatography carrier and an anion exchanger, and by salting-out to thereby obtain a pure form of human serum albumin which contains substantially no proteinous and polysaccharide contaminants, which is formulated into a pharmaceutical preparation. The thus obtained human serum albumin can further be purified by treating recombinant human serum albumin with a hydrophobic chromatography carrier at pH of 2 to 5 and a salt concentration of 0.4 to 1 and exposing the carrier to a pH of 6 to 8 and a salt concentration of 0.01 to 0.Type: GrantFiled: February 25, 1994Date of Patent: May 28, 1996Assignee: The Green Cross CorporationInventors: Takao Ohmura, Akinori Sumi, Wataru Ohtani, Naoto Furuhata, Kazuya Takeshima, Kaeko Kamide, Munehiro Noda, Masahide Kondo, Syoichi Ishikawa, Kazuhiro Oohara, Kazumasa Yokoyama, Nagatoshi Fujiwara
-
Patent number: 5440018Abstract: Human serum albumin obtained by gene manipulation techniques can be purified by a combination of specified steps in which a culture supernatant obtained from a human serum albumin-producing host is subjected to ultrafiltration, heat treatment, acid treatment and another ultrafiltration, followed by subsequent treatments with a cation exchanger, a hydrophobic chromatography carrier and an anion exchanger, and by salting-out to thereby obtain a pure form of human serum albumin which contains substantially no proteinous and polysaccharide contaminants, which is formulated into a pharmaceutical preparation. This process makes it possible to effeciently purify recombinant human serum albumin and to provide substantially pure human serum albumin which does not contain producer host-related substances and other contaminants and is sufficiently free from coloration.Type: GrantFiled: March 24, 1993Date of Patent: August 8, 1995Assignee: The Green Cross CorporationInventors: Takao Ohmura, Akinori Sumi, Wataru Ohtani, Naoto Fuluhata, Kazuya Takeshima, Kaeko Kamide, Munehiro Noda, Masahide Kondo, Syoichi Ishikawa, Kazuhiro Oohara, Kazumasa Yokoyama
-
Patent number: 5219995Abstract: The present invention describes a process for activating Factor II to Factor II.sub.a by incubating Factor II in the presence of Factor V, Factor X.sub.a, phospholipids, and calcium ions. Each of the factors is prepared from a single impure protein fraction which includes Factors II, V and X. The Factor II, V and X purification procedure comprises the steps of DEAE ligand chromatography and precipitation by the addition of barium chloride. Factor V is recovered from the barium chloride supernatant, and Factors II and X are contained in the barium chloride precipitate. The barium chloride precipitate is dissolved in an aqueous solution and is applied to a chromatographic resin coupled with a ligand which binds Factor X and Factor II weakly or not at all. Factor II is recovered from the fraction, which remains unbound or weakly bound to the Factor X binding ligand. Factor X.sub.Type: GrantFiled: July 14, 1992Date of Patent: June 15, 1993Assignee: Alpha Therapeutic CorporationInventors: Steven W. Herring, Yahiro Uemura, Munehiro Noda, Kenneth T. Shitanishi
-
Patent number: PP11428Abstract: The present invention relates to a variety obtained by selecting and cross-breeding those individuals producing the insect resistance substance peramine from Glyceria ischyroneura Steud. growing wild in various districts of Japan.Type: GrantFiled: September 26, 1997Date of Patent: June 27, 2000Assignee: Shibaura Institute of TechnologyInventors: Satoshi Shinozaki, Hiroyuki Sano, Naoya Hiruma, Takahiro Imada, Munehiro Noda, Fumiyoshi Akaike, Sachiko Yamashima, Madoka Kon